Finally, common alterations in SCLC, such as MYC amplification, have been shown to correlate with response to DNA-targeting agents such as CHEK1 inhibitors and in combination with cisplatin and olaparib, providing a rationale that subtypes of SCLC could be more vulnerable to DDR inhibition [97]. This evidence concerns the gene MYC and small cell lung carcinoma.